Livforsakringsbolaget Skandia, Omsesidigt 13F: Adds $11M to VRTX Stake

Livforsakringsbolaget Skandia boosted its holdings in Vertex Pharmaceuticals Incorporated VRTX by 21,920 shares during the quarter, ending with 27,700 shares worth about $14.5 million according to a form 13f filing with the securities and exchange commission on october 21 2026.

VRTX Vertex Pharmaceuticals Incorporated

$524.52 ▲ +16.01% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Livforsakringsbolaget Skandia's Vertex Pharmaceuticals Position

The institutional investor expanded its position significantly during the period. The purchase of 21,920 shares marked a 379.2% increase from the prior holding of 5,780 shares. The resulting stake of 27,700 shares reflects a larger bet on the biotechnology developer as the shares trade above both short and long-term trend lines.

Other Institutional Activity in Vertex Pharmaceuticals

Other large money managers adjusted their holdings around the same time. Capital International Investors reduced its holdings by 431,119 shares, ending with 4,695,144 shares worth about $2.5 billion, which represented an 8.4% decrease for the fund's position.

Vertex Pharmaceuticals Incorporated Stock Up 1.2%

Vertex Pharmaceuticals shares recently traded around $530.98 as of october 22 2026, up about 1.2% from the closing price of $524.52 on the filing date. The stock closed that day well above its 50-day moving average of $522.37 and significantly higher than its 200-day moving average of $476.84. The share price sits 5.2% below its 52-week high of $560.25 and 31.7% above its 52-week low of $403.16.

Recent Earnings

Vertex Pharmaceuticals reported $12.6 billion in trailing twelve month revenue alongside earnings of $17.27 per share. The business posted a net profit margin of 35.0% and a return on equity of 23.5%. Investors will watch for the company's upcoming financial results on november 2 2026.

Insider Buying and Selling at Vertex Pharmaceuticals Incorporated

Several company insiders sold shares during the summer months. On june 26 2026, officer Carmen Bozic sold 596 shares at an average price of $482.50 for a total of $287,570. On july 1 2026, officer Joy Liu sold 828 shares at $502.71 each, totaling $416,244. The next day, on july 2 2026, officer Duncan J. Mckechnie sold 1,541 shares at $519.00 for $799,779, and officer Ourania Tatsis sold 1,500 shares at $524.99 for $787,485.

Analysts Set New Price Targets

Wall street firms updated their views on the stock through the late summer and early fall. TD Cowen maintained a buy rating on august 4 2026 with a price target raised to $550.00. Truist Securities maintained a buy rating on august 5 2026 while lifting its target to $565.00. Barclays maintained an overweight rating on august 5 2026 and moved its target to $617.00. UBS maintained a buy rating on september 28 2026 with a target of $615.00, and RBC Capital maintained an outperform rating on october 8 2026 while taking its target to $576.00. Wall street analysts carry a consensus buy recommendation on the stock with a mean price target of $571.46.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company that discovers and develops transformative medicines for serious human diseases. The firm focuses heavily on specialty markets including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain treatments across international markets.

Bottom Line

Institutional interest in the biotechnology firm remains active as major funds adjust their exposure. Market participants are monitoring upcoming financial results scheduled for november 2 2026 to gauge ongoing product adoption and financial health.